DNA Polymerase Beta Catalytic and Fidelity Mutations Drive Platinum Specific Drug Sensitivity
Jacob Lindquist, Joshua R. Heyza, Istri Ndoja, Nasrin Movahhedin, Chris Yunker, Marina Cardó‐Vila, Seongho Kim, Joann Sweasy, Steve M. Patrick
This study identifies Polβ mutations that drive sensitivity to cisplatin and carboplatin in TNBC models, suggesting their use as predictive biomarkers for platinum-based therapies.
Cancers · Aug 7, 2026Peer-reviewedCancer Biology